Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy
Prostate specific membrane antigen positron-emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) in prostate cancer (PCa) patients with biochemical recurrence/persistence after prostatectomy. This work examines (i) metastasis-free survival (MFS) following PSMA-PET...
Saved in:
Published in | International journal of radiation oncology, biology, physics |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
02.06.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | Prostate specific membrane antigen positron-emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) in prostate cancer (PCa) patients with biochemical recurrence/persistence after prostatectomy. This work examines (i) metastasis-free survival (MFS) following PSMA-PET guided sRT and (ii) the metastatic patterns on PSMA-PET images after sRT.
This retrospective, multicenter (9 centers, 5 countries) study included patients referred for PSMA-PET due to recurrent/persistent disease after prostatectomy. Patients with distant metastases (DM) on PSMA-PET prior to sRT were excluded. Cox-regression was performed to assess the impact of clinical parameters on MFS. The distribution of PSMA-PET detected DM following sRT and their respective risk factors were analysed.
All (n=815) patients received intensity-modulated RT to the prostatic fossa. In case of PET-positive pelvic lymph nodes (PLN-PET, n=275, 34%), pelvic lymphatics had been irradiated. Androgen deprivation therapy had been given in 251 (31%) patients. The median follow-up after sRT was 36 months. The 2-/4-year MFS following sRT were 93%/81%. In multivariate analysis the presence of PLN-PET was a strong predictor for MFS (HR=2.39, p<0.001). Following sRT, DM were detected by PSMA-PET in 128/198 (65%) patients and two metastatic patterns were observed: 43% had DM in sub diaphragmatic paraaortic LNs (abdominal-lymphatic) whereas 45% in bones, 9% in supra diaphragmatic LNs and 6% in visceral organs (distant). Two distinct signatures with risk factors for each pattern were identified.
MFS in our study is lower compared to previous studies, obviously due to the higher detection rate of DM in PSMA-PET after sRT. Thus, it remains unclear whether MFS is a surrogate endpoint for overall survival in PSMA PET-staged patients in the post sRT setting. PLN-PET may be proposed as a new surrogate parameter predictive of MFS. Analysis of recurrence patterns in PET after sRT revealed risk factor signatures for two metastatic patterns (abdominal-lymphatic and distant), which may allow individualized sRT concepts in the future. |
---|---|
AbstractList | Prostate specific membrane antigen positron-emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) in prostate cancer (PCa) patients with biochemical recurrence/persistence after prostatectomy. This work examines (i) metastasis-free survival (MFS) following PSMA-PET guided sRT and (ii) the metastatic patterns on PSMA-PET images after sRT.
This retrospective, multicenter (9 centers, 5 countries) study included patients referred for PSMA-PET due to recurrent/persistent disease after prostatectomy. Patients with distant metastases (DM) on PSMA-PET prior to sRT were excluded. Cox-regression was performed to assess the impact of clinical parameters on MFS. The distribution of PSMA-PET detected DM following sRT and their respective risk factors were analysed.
All (n=815) patients received intensity-modulated RT to the prostatic fossa. In case of PET-positive pelvic lymph nodes (PLN-PET, n=275, 34%), pelvic lymphatics had been irradiated. Androgen deprivation therapy had been given in 251 (31%) patients. The median follow-up after sRT was 36 months. The 2-/4-year MFS following sRT were 93%/81%. In multivariate analysis the presence of PLN-PET was a strong predictor for MFS (HR=2.39, p<0.001). Following sRT, DM were detected by PSMA-PET in 128/198 (65%) patients and two metastatic patterns were observed: 43% had DM in sub diaphragmatic paraaortic LNs (abdominal-lymphatic) whereas 45% in bones, 9% in supra diaphragmatic LNs and 6% in visceral organs (distant). Two distinct signatures with risk factors for each pattern were identified.
MFS in our study is lower compared to previous studies, obviously due to the higher detection rate of DM in PSMA-PET after sRT. Thus, it remains unclear whether MFS is a surrogate endpoint for overall survival in PSMA PET-staged patients in the post sRT setting. PLN-PET may be proposed as a new surrogate parameter predictive of MFS. Analysis of recurrence patterns in PET after sRT revealed risk factor signatures for two metastatic patterns (abdominal-lymphatic and distant), which may allow individualized sRT concepts in the future. |
Author | Fendler, Wolfgang P Hruby, George Medici, Federica Henkenberens, Christoph Trapp, Christian Strouthos, Iosif Combs, Stephanie E Spohn, Simon K B Guckenberger, Matthias Ferentinos, Konstantinos Lanzafame, Helena Miksch, Jonathan Farolfi, Andrea Vogel, Marco M E Wiegel, Thomas Vrachimis, Alexis Peeken, Jan C Grosu, Anca-Ligia Cavallini, Letizia Emmett, Louise Zamboglou, Constantinos Ceci, Francesco Schmidt-Hegemann, Nina Sophie Kirste, Simon Morganti, Alessio Guiseppe Sahlmann, Joerg Serani, Francesca Ruf, Juri Koerber, Stefan A Schiller, Kilian Gratzke, Christian Fanti, Stefano Eiber, Matthias Kroeze, Stephanie |
Author_xml | – sequence: 1 givenname: Constantinos surname: Zamboglou fullname: Zamboglou, Constantinos email: constantinos.zamboglou@uniklinik-freiburg.de organization: Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany; Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Germany; German Oncology Center, University Hospital of the European University, Limassol, Cyprus. Electronic address: constantinos.zamboglou@uniklinik-freiburg.de – sequence: 2 givenname: Iosif surname: Strouthos fullname: Strouthos, Iosif organization: Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus – sequence: 3 givenname: Joerg surname: Sahlmann fullname: Sahlmann, Joerg organization: Institute of Medical Biometry and Statistics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany – sequence: 4 givenname: Andrea surname: Farolfi fullname: Farolfi, Andrea organization: Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy – sequence: 5 givenname: Francesca surname: Serani fullname: Serani, Francesca organization: Division of Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy – sequence: 6 givenname: Federica surname: Medici fullname: Medici, Federica organization: Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy – sequence: 7 givenname: Letizia surname: Cavallini fullname: Cavallini, Letizia organization: Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy – sequence: 8 givenname: Alessio Guiseppe surname: Morganti fullname: Morganti, Alessio Guiseppe organization: Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy – sequence: 9 givenname: Christian surname: Trapp fullname: Trapp, Christian organization: Department of Radiation Oncology, University Hospital, LMU Munich – sequence: 10 givenname: Stefan A surname: Koerber fullname: Koerber, Stefan A organization: Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany – sequence: 11 givenname: Jan C surname: Peeken fullname: Peeken, Jan C organization: Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Germany; Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum, München, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany – sequence: 12 givenname: Marco M E surname: Vogel fullname: Vogel, Marco M E organization: Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Germany; Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum, München, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany – sequence: 13 givenname: Kilian surname: Schiller fullname: Schiller, Kilian organization: Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Germany; Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum, München, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany – sequence: 14 givenname: Stephanie E surname: Combs fullname: Combs, Stephanie E organization: Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Germany; Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum, München, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany – sequence: 15 givenname: Matthias surname: Eiber fullname: Eiber, Matthias organization: Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich (TUM), Germany – sequence: 16 givenname: Alexis surname: Vrachimis fullname: Vrachimis, Alexis organization: Department of Nuclear Medicine, German Oncology Center, University Hospital of the European University, Limassol, Cyprus; C.A.R.I.C. Cancer Research & Innovation Center, Limassol, Cyprus – sequence: 17 givenname: Konstantinos surname: Ferentinos fullname: Ferentinos, Konstantinos organization: Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus – sequence: 18 givenname: Simon K B surname: Spohn fullname: Spohn, Simon K B organization: Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany; Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Germany – sequence: 19 givenname: Simon surname: Kirste fullname: Kirste, Simon organization: Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany – sequence: 20 givenname: Christian surname: Gratzke fullname: Gratzke, Christian organization: Department of Urology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany – sequence: 21 givenname: Juri surname: Ruf fullname: Ruf, Juri organization: Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany – sequence: 22 givenname: Anca-Ligia surname: Grosu fullname: Grosu, Anca-Ligia organization: Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany – sequence: 23 givenname: Francesco surname: Ceci fullname: Ceci, Francesco organization: Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy – sequence: 24 givenname: Wolfgang P surname: Fendler fullname: Fendler, Wolfgang P organization: Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany – sequence: 25 givenname: Jonathan surname: Miksch fullname: Miksch, Jonathan organization: Department of Nuclear Medicine, University Hospital of Ulm, Ulm, Germany – sequence: 26 givenname: Stephanie surname: Kroeze fullname: Kroeze, Stephanie organization: Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Switzerland – sequence: 27 givenname: Matthias surname: Guckenberger fullname: Guckenberger, Matthias organization: Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Switzerland – sequence: 28 givenname: Helena surname: Lanzafame fullname: Lanzafame, Helena organization: Division of Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy – sequence: 29 givenname: Stefano surname: Fanti fullname: Fanti, Stefano organization: Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy – sequence: 30 givenname: George surname: Hruby fullname: Hruby, George organization: Department of Radiation Oncology, Royal North Shore Hospital - University of Sydney, Australia – sequence: 31 givenname: Thomas surname: Wiegel fullname: Wiegel, Thomas organization: Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany – sequence: 32 givenname: Louise surname: Emmett fullname: Emmett, Louise organization: Department of Theranostics and Nuclear medicine, St Vincent's Hospital Sydney Australia; St Vincent's Clinical School, University of New South Wales, Sydney Australia – sequence: 33 givenname: Nina Sophie surname: Schmidt-Hegemann fullname: Schmidt-Hegemann, Nina Sophie organization: Department of Radiation Oncology, University Hospital, LMU Munich – sequence: 34 givenname: Christoph surname: Henkenberens fullname: Henkenberens, Christoph organization: Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35659629$$D View this record in MEDLINE/PubMed |
BookMark | eNqFj89qwzAMh83Y6J-1rzD0AoZkadrlOEbHLoXCetitqLbSeiS2kZ1AHmrvOIeu54FA6MenT2gu7q2zdCdm-cumkkVZfk3FPITvLMvyfLOaiGlRrstq_VzNxM-OIoZUJsiaiSB03JseG0CrwWOMxDaAq0GbhNkI7XUhGjVGhIEA60TB_nP3Kvfbgzx3RpOGgE2PZwJGbVy8EKMfwFhgUh0zJZVj8MTpdBwnz270Eii0Kvmu1luqomuHhXiosQm0_OuP4ul9e3j7kL47taSPnk2LPBxv_xX_Ar-lHWKL |
ContentType | Journal Article |
Copyright | Copyright © 2022 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. |
DBID | NPM |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-355X |
ExternalDocumentID | 35659629 |
Genre | Journal Article |
GroupedDBID | --- --K .1- .FO 0R~ 1B1 1P~ 1RT 1~5 4.4 457 4G. 53G 5RE 7-5 AAEDT AAEDW AAIAV AALRI AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ADBBV AENEX AEVXI AFCTW AFRHN AFTJW AHHHB AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY DU5 EBS EFJIC F5P FDB GBLVA HED HMO IHE J1W KOM LX3 M41 MO0 NPM O9- OC~ OO- RIG RNS ROL RPZ SDG SEL SES SSZ UV1 XH2 Z5R ZA5 ~S- |
ID | FETCH-pubmed_primary_356596293 |
IngestDate | Thu May 23 23:34:09 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | Copyright © 2022 Elsevier Ltd. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-pubmed_primary_356596293 |
PMID | 35659629 |
ParticipantIDs | pubmed_primary_35659629 |
PublicationCentury | 2000 |
PublicationDate | 2022-Jun-02 |
PublicationDateYYYYMMDD | 2022-06-02 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-Jun-02 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | International journal of radiation oncology, biology, physics |
PublicationTitleAlternate | Int J Radiat Oncol Biol Phys |
PublicationYear | 2022 |
SSID | ssj0001174 |
Score | 4.4663305 |
Snippet | Prostate specific membrane antigen positron-emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) in prostate cancer (PCa)... |
SourceID | pubmed |
SourceType | Index Database |
Title | Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35659629 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa6IlV7QRu3jcF0HnhDRoQ0WfpYTUNjU9FEi6h4qezEHkFtXOUyCf7IfsX-445jO0krJgEvUWu7p0q-r8nn03Mh5E0o5ckwED6VUSLoUPKYchZwGrKh9N7zcCTqpn2Tz-H51-HFPJj3eredqKWq5O_i33_MK_kfVHEMcdVZsv-AbGMUB_A14otHRBiPf4XxRJQM1V2RFlTmQrwtKvzh37js_7pypolyS7RKzErdL1p_QBdptf_M2CbhV9PJmF6dzeh1lSaoQQu2vNHRPDlLUpuj9cukvsS2oJPKdcnjQrME36118gjKVh1EFqM9Y9WNxqVLnPjZBs63fshO9Qr9fVbEZnGTSMPbnBrjiWk2At_Ziqvrpapqh6_RumWaqWbBtMx1k0ATTPhJFalsZtiP5cq1iFau0JepS6mWMm3CPVnXM4Kbau0cMbd2Ye7m0cmIoqCad58VCOF6VRPCRzE7Cq3DZbPotpvaITu-F_TJo_Hll2-XzSPew33cLhm4VVtbklqazPbIY7ungLEhyD7piewJGUxs1MRTcrfFE3A8AeQJOJ6AkmB5Ai1PwPIEakRhiydgeQJdnkCaQcMTUDm0PAHHCDA8sVY3ePKMHH88m52eU3Oyi7Wph7Jwl8F_TvqZysQBAe77gfDYh4jzBGWSN4okrkJ1zyPdR5kdkhcPGHn54MwR2W1RfkX6ZV6J16gIS35s8bkHkU17FQ |
link.rule.ids | 315,786,790 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metastasis-free+survival+and+patterns+of+distant+metastatic+disease+after+PSMA-PET-guided+salvage+radiotherapy+in+recurrent+or+persistent+prostate+cancer+after+prostatectomy&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Zamboglou%2C+Constantinos&rft.au=Strouthos%2C+Iosif&rft.au=Sahlmann%2C+Joerg&rft.au=Farolfi%2C+Andrea&rft.date=2022-06-02&rft.eissn=1879-355X&rft_id=info%3Apmid%2F35659629&rft.externalDocID=35659629 |